Czech Lymphoma Study Group
Prednisone tablet(Czech Lymphoma Study Group)은 Lymphoma, T-Cell, Peripheral 표적 ADC로, Lymphoma, T-Cell, Peripheral 영역에서 개발·상용화 중입니다. 작용기전: targets two oncogenic drivers: homologous recombination repair (HRR) gene alterations and the androgen-receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 16.8% (ClinicalTrials.gov NCT03834519). 차별점: novel drugs, such as SEGRAs or liposomal glucococorticoids, trying to improve their benefit/risk ratio.
Lymphoma, T-Cell, Peripheral
Lymphoma, T-Cell, Peripheral
Active
bispecific antibody (KN046) that blocks both programmed death ligand-1
novel drugs, such as SEGRAs or liposomal glucococorticoids, trying to improve their benefit/risk ratio
targets two oncogenic drivers: homologous recombination repair (HRR) gene alterations and the androgen-receptor
PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), follow
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Czech Lymphoma Study Group
Prednisone tablet(Czech Lymphoma Study Group)은 Lymphoma, T-Cell, Peripheral 표적 ADC로, Lymphoma, T-Cell, Peripheral 영역에서 개발·상용화 중입니다. 작용기전: targets two oncogenic drivers: homologous recombination repair (HRR) gene alterations and the androgen-receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 16.8% (ClinicalTrials.gov NCT03834519). 차별점: novel drugs, such as SEGRAs or liposomal glucococorticoids, trying to improve their benefit/risk ratio.
Lymphoma, T-Cell, Peripheral
Lymphoma, T-Cell, Peripheral
Active
bispecific antibody (KN046) that blocks both programmed death ligand-1
novel drugs, such as SEGRAs or liposomal glucococorticoids, trying to improve their benefit/risk ratio
targets two oncogenic drivers: homologous recombination repair (HRR) gene alterations and the androgen-receptor
PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), follow
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.